Patients with bone metastasis of lung adenocarcinoma are recommended to take bone-protecting injection, which can inhibit bone destruction. However, if some patients are intolerant to drugs or allergic to drugs, they may not need to take bone protection injections, which should follow the diagnosis and treatment advice of specialists. Most of lung adenocarcinoma bone metastases are osteolytic bone metastases, which are characterized by local bone and joint pain, swelling, and pathological fracture in serious cases. Osteoprotective injection generally refers to drugs such as zoledronate and ibandronate, which can play a certain inhibitory effect on osteolytic bone metastasis caused by malignant tumors, and at the same time, can alleviate clinical symptoms such as bone pain. Therefore, bone protection injection has a certain protective effect on patients with bone metastasis of lung adenocarcinoma. However, a small portion of lung adenocarcinoma may cause osteogenic bone metastasis, which is mainly reflected in the metastatic lesion bone hyperplasia, and there is no therapeutic effect of bone-saver needles. In addition, the application of bone-saver may have adverse reactions such as osteonecrosis of the jaw and renal function damage, and some patients may be allergic to the drugs, so the application of bone-saver is not recommended in the above cases. In conclusion, bone metastasis of lung adenocarcinoma should be treated with bone-saver under the guidance of specialized doctors, and should not be applied or stopped by oneself.